Clinical trials: Myeloproliferative Neoplasms
Leukemia, Myeloid, Chronic
AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™
This is a Phase II, exploratory, open-label study of the investigational product AG-858, in patients who are cytogenetically positive after treatment with Gleevec.
- Trial name
- NCT00058747
- Testing
- Autologous HSP-70 Protein-Peptide Complex (AG-858) Plus Gleevec™.
- Where
- 13 sites in United States, United Kingdom
- Volunteers
- 40 people
- Sponsor
- Agenus Inc.
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)
This study seeks to (i) determine a safe and tolerated dose of CYT387 (momelotinib) given to patients with PMF, post-PV or post-ET and, (ii) assess the effectiveness of orally-administered CYT387 as a treatment for PMF, post-PV…
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
- Trial name
- NCT00935987
- Testing
- CYT387
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 166 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Essential Thrombocythemia
French Observational Xagrid (FOX) Study In Adult Patients With Essential Thrombocythemia
This is an observational study to explore how different treatment regimens affect continuation with treatment in the first 6 months following initiation of XAGRID into adult patients' essential thrombocythemia therapy.
- Trial name
- FOX (NCT01192347)
- Where
- 46 sites in France
- Volunteers
- 177 people
- Sponsor
- Shire
Primary Myelofibrosis, Post-Polycythemia Vera
Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis
The myeloproliferative neoplasms (MPN), most notably polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are a diverse but inter-related suite of clonal disorders of pluripotent hematopoietic…
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis
- Trial name
- NCT01423058
- Testing
- Momelotinib
- Where
- 6 sites in United States, Canada
- Volunteers
- 61 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Leukemia, Myeloid, Chronic-Phase
Treatment Patterns and Key Endpoints Among Patients With Chronic-Phase Chronic Myeloid Leukemia in a Community Oncology Setting
This was a retrospective observational study to examine treatment patterns, molecular testing patterns, treatment response, and clinical outcomes among patients initiating first-line (1L) tyrosine kinase inhibitor (TKI) treatment…
- Trial name
- NCT07374120
- Where
- United States
- Volunteers
- 1,480 people
- Sponsor
- Novartis Pharmaceuticals
CML, Chronic Phase, CML, Accelerated Phase
A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.
HS-10382 is a small molecular, oral potent, allosteric inhibitor. By binding a myristoyl site of the BCR-ABL1 protein, HS-10382 locks BCR-ABL1 into an inactive conformation.
- Trial name
- NCT05367700
- Testing
- HS-10382(Part 1: Dose escalation), HS-10382(Part 2: Dose expansion)
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Acute Myeloid Leukemia
A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms
Phase I, multicenter study to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy of HMPL-306 in Patients of Relapsed/Refractory Myeloid Leukemia/Neoplasms with IDH1 and/or IDH2 Mutation.
- Trial name
- NCT04272957
- Testing
- HMPL-306
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Hutchison Medipharma Limited
AML, Acute Myeloid Leukemia
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
This is a two Part study in patients with relapsed/refractory acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), or high risk myelodysplastic syndrome (MDS) that will initially evaluate the safety and…
- Conditions
- AML, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, CMML
- Trial name
- NCT04358393
- Testing
- APG-115, 5-azacitidine
- Where
- 8 sites in United States
- Volunteers
- 69 people
- Sponsor
- Ascentage Pharma Group Inc.
Hematological Malignancies
Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
The purpose of this research study is to find out more information relating to the highest dose of KCP-330 that can be given safely and side effects it may cause, to examine how the body affects KCP-330 concentrations in the…
- Trial name
- NCT01607892
- Testing
- KPT-330
- Where
- 12 sites in United States, Canada and 1 more
- Volunteers
- 286 people
- Sponsor
- Karyopharm Therapeutics Inc
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
This study is a dose escalation, and cohort expansion study in subjects with advanced cancer for which no standard therapy exists. Subjects must have received prior treatment for cancer that has not worked, or has stopped working.
- Conditions
- Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Lymphoma, Follicular, Cancer
- Trial name
- NCT02440685
- Testing
- ASN002 Dose Escalation, ASN002 RD
- Where
- 14 sites in United States, Argentina
- Volunteers
- 51 people
- Sponsor
- Asana BioSciences
Myelofibrosis, Myeloproliferative Disorders
A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis
The study consists of two phases: The first portion of the study is a Phase 1 dose escalation study to determine the maximum tolerated dose and the dose limiting toxicities of SB1518 when given as a single agent orally once daily…
- Conditions
- Myelofibrosis, Myeloproliferative Disorders, Polycythemia Vera, Essential Thrombocythemia
- Trial name
- NCT00745550
- Testing
- SB1518
- Where
- 6 sites in United States, Australia
- Volunteers
- 55 people
- Sponsor
- S*BIO
Chronic Myeloid Leukemia
Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia
This is a efficacy and safety study of imatinib Mesylate Capsule as First line treatment in patients with chronic phase of Chronic Myeloid Leukemia.
- Trial name
- NCT02317159
- Testing
- Imatinib
- Volunteers
- 90 people
- Sponsor
- Cttq
Acute Lymphocytic Leukemia, Acute Myeloid Leukemia
Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers
This study hopes to show that specially treated umbilical cord cells, called stem cells, can be safely given to a person after they receive chemoradiation therapy or chemotherapy for their illness.
- Conditions
- Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma
- Trial name
- NCT00089596
- Testing
- Expansion of umbilical cord stem cells
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- ViaCell
Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Chronic Myeloid Leukemia, Chronic Phase
A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)
Researchers are looking for a new way to treat a blood cancer called chronic myeloid leukemia (CML). Researchers want to learn if MK-4208 (Tern-701) can treat this type of blood cancer.
- Conditions
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia
- Trial name
- CARDINAL (NCT06163430)
- Testing
- MK-4208
- Where
- 54 sites in United States, Australia and 7 more
- Volunteers
- 330 people
- Sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Primary Myelofibrosis (PMF), Post Polycythaemia Myelofibrosis (PPV MF)
Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
The primary objective of this study is to evaluate the efficacy of INC424 in patients with PMF, PPV MF, or PET-MF using a composite measure of either an objective endpoint (> 50% reduction in splenomegaly using palpitation at 48…
- Conditions
- Primary Myelofibrosis (PMF), Post Polycythaemia Myelofibrosis (PPV MF), Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
- Trial name
- MACS2030 (NCT01558739)
- Testing
- INC424
- Where
- 10 sites in United Kingdom
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myeloid Leukaemia
A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands
The purpose of this study is to describe the efficacy and safety of bosutinib in patients with chronic myeloid leukaemia used in a real world setting
- Trial name
- NCT02546375
- Testing
- Bosutinib
- Where
- 3 sites in United Kingdom
- Volunteers
- 87 people
- Sponsor
- Pfizer
Hematologic Malignancy, Acute Leukemia
Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies
Prospective, multi-center open label study of HLA-partially to fully matched allogeneic cryopreserved deceased donor bone marrow transplantation and living donor transplantation for patients with hematologic malignancies.
- Conditions
- Hematologic Malignancy, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT07710781
- Testing
- Ossium HPC, Marrow, Standard of care living donor - Haplo Related, Standard of care living donor - Mismatched Unrelated
- Volunteers
- 300 people
- Sponsor
- Ossium Health, Inc.
Leukemia, Chronic Myelogenous
Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Phase 2, single-arm, open-label trial. Patients will receive bosutinib for the duration of the study.
- Trial name
- NCT03128411
- Testing
- Bosutinib
- Where
- 21 sites in Japan
- Volunteers
- 64 people
- Sponsor
- Pfizer
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia
This is a multi-center, open-label, non-randomized, two-part Phase I/Ib study of RP7214 in combination with azacitidine in patients with AML, MDS and CMML.
- Conditions
- Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT05246384
- Testing
- RP7214
- Sponsor
- Rhizen Pharmaceuticals SA
Leukemia, Myelogenous, Chronic
A Bioequivalence Study of Dasatinib Tablet
This is a clinical study to evaluate the bioequivalence of dasatinib tablet produced by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Trial name
- NCT05640804
- Testing
- CTTQ Dasatinib tablet, Sprycel Dasatinib tablet
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.